Results 1 to 10 of about 86,962 (305)

Development of the accredited duchenne centers program, a global program to achieve uniform and up-to-date care for all people living with duchenne muscular dystrophy [PDF]

Orphanet Journal of Rare Diseases
The Accredited Duchenne Centers (ADC) Program is a global program initiated by the World Duchenne Organization (WDO). The aim of the ADC Program is to achieve global, uniform and up-to-date care for all people living with Duchenne Muscular Dystrophy (DMD)
Imelda J. M. de Groot, Karolina Podolská, Nathalie Goemans, Suzie-Ann Bakker, Nawel Lalout, Merel Jansen, Elizabeth Vroom   +6 more
doaj   +2 more sources

Duchenne muscular dystrophy [PDF]

Nature Reviews Disease Primers, 2021
Duchenne muscular dystrophy is a severe, progressive, muscle-wasting disease that leads to difficulties with movement and, eventually, to the need for assisted ventilation and premature death. The disease is caused by mutations in DMD (encoding dystrophin) that abolish the production of dystrophin in muscle.
Duan, Dongsheng, Goemans, Nathalie, Takeda, Shin'ichi, Mercuri, Eugenio, Aartsma-Rus, Annemieke   +4 more
openaire   +6 more sources

Genetic modifiers of Duchenne muscular dystrophy and dilated cardiomyopathy [PDF]

, 2015
OBJECTIVE: Dilated cardiomyopathy (DCM) is a major complication and leading cause of death in Duchenne muscular dystrophy (DMD). DCM onset is variable, suggesting modifier effects of genetic or environmental factors.
Angelini, Corrado, Barp, Andrea, Bello, Luca, Calore, Chiara, Calvo, Vincenzo, Comi, Gp, Ermani, Mario, Gorni, K, Hoffman, Ep, Magri, F, Melacini, Paola, Messina, S, Pantic, Boris, Pegoraro, Elena, Picillo, E, Politano, L, Polo, Angela, Semplicini, Claudio, Soraru', Gianni, Taglia, A, Vianello, Sara, Vita, G, Vita, Gl   +22 more
core   +20 more sources

The achievement of Duchenne. [PDF]

Proceedings of the Royal Society of Medicine, 1973
E. D. R. Campbell
openalex   +4 more sources

Patient-led development of digital endpoints and the use of computer vision analysis in assessment of motor function in rare diseases

Frontiers in Pharmacology, 2022
Digital health technologies are transforming the way health outcomes are captured and measured. Digital biomarkers may provide more objective measurements than traditional approaches as they encompass continuous and longitudinal data collection and use ...
Elisa Ferrer-Mallol, Clare Matthews, Madeline Stoodley, Alessandra Gaeta, Elinor George, Emily Reuben, Alex Johnson, Elin Haf Davies   +7 more
doaj   +1 more source

Single nuclei transcriptomics of muscle reveals intra-muscular cell dynamics linked to dystrophin loss and rescue

Communications Biology, 2022
A method to isolate and sequence individual nuclei from human and mouse muscle biopsies provides further insight into the mechanisms of dystrophin loss and repair, in the context of Duchenne muscular dystrophy.
Deirdre D. Scripture-Adams, Kevin N. Chesmore, Florian Barthélémy, Richard T. Wang, Shirley Nieves-Rodriguez, Derek W. Wang, Ekaterina I. Mokhonova, Emilie D. Douine, Jijun Wan, Isaiah Little, Laura N. Rabichow, Stanley F. Nelson, M. Carrie Miceli   +12 more
doaj   +1 more source

Protective role of γ ⁃ tocotrienol on muscle satellite cells of Duchenne muscular dystrophy in mice

Chinese Journal of Contemporary Neurology and Neurosurgery, 2022
Objective To investigate the damage of skeletal muscle satellite cells in Duchenne muscular dystrophy (DMD) and the protective effect of γ⁃tocotrienol (GT3) on muscle satellite cells in DMD knockout mice.
YANG Shuo , ZHAO Hui⁃wen, YANG Juan, ZENG Hui⁃hong, KUANG Bo⁃hai, SHAO Li⁃jian   +5 more
doaj   +1 more source

Resveratrol Promotes Hypertrophy in Wildtype Skeletal Muscle and Reduces Muscle Necrosis and Gene Expression of Inflammatory Markers in Mdx Mice

Molecules, 2021
Duchenne muscular dystrophy (DMD) is a progressive fatal neuromuscular disorder with no cure. Therapies to restore dystrophin deficiency have been approved in some jurisdictions but long-term effectiveness is yet to be established.
Keryn G. Woodman, Chantal A. Coles, Shireen R. Lamandé, Jason D. White   +3 more
doaj   +1 more source

Update of the Brazilian consensus recommendations on Duchenne muscular dystrophy

Arquivos de Neuro-Psiquiatria, 2023
In the last few decades, there have been considerable improvements in the diagnosis and care of Duchenne muscular dystrophy (DMD), the most common childhood muscular dystrophy. International guidelines have been published and recently reviewed.
Alexandra Prufer de Queiroz Campos Araujo, Jonas Alex Morales Saute, Clarisse Pereira Dias Drumond Fortes, Marcondes Cavalcante França Jr, Jaqueline Almeida Pereira, Marco Antonio Veloso de Albuquerque, Alzira Alves de Siqueira Carvalho, Eduardo Boiteux Uchôa Cavalcanti, Anna Paula Paranhos Miranda Covaleski, Simone Chaves Fagondes, Juliana Gurgel-Giannetti, Marcus Vinicius Magno Gonçalves, Alberto Rolim Muro Martinez, Antônio Rodrigues Coimbra Neto, Flavio Reis Neves, Anamarli Nucci, Ana Paula Cassetta dos Santos Nucera, Andre Luis Santos Pessoa, Marcos Ferreira Rebel, Flavia Nardes dos Santos, Rosana Herminia Scola, Cláudia Ferreira da Rosa Sobreira   +21 more
doaj   +1 more source

Duchenne expert physician perspectives on Duchenne newborn screening and early Duchenne care

American Journal of Medical Genetics Part C: Seminars in Medical Genetics, 2022
AbstractDuchenne muscular dystrophy (DMD) is a progressive, fatal neuromuscular disorder typically diagnosed between 4 and 5 years of age. DMD currently has five FDA approved therapies, which has led to increased interest in newborn screening (NBS) for DMD.
Niki Armstrong, Rachel Schrader, Ryan Fischer, Norah Crossnohere   +3 more
openaire   +2 more sources